New Cocrystals of Ligustrazine: Enhancing Hygroscopicity and Stability-Reference-Cited by-同舟云学术

New Cocrystals of Ligustrazine: Enhancing Hygroscopicity and Stability

Published:2024-05-08 Issue:10 Volume:29 Page:2208
ISSN:1420-3049
Container-title:Molecules
language:en
Short-container-title:Molecules

Author:

Xie Yifei¹^ORCID,Gong Lixiang²,Tao Yue²,Zhang Baoxi²,Zhang Li²,Yang Shiying²^ORCID,Yang Dezhi²^ORCID,Lu Yang²,Du Guanhua¹

Affiliation:

1. Beijing City Key Laboratory of Drug Target and Screening Research, National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China

2. Beijing City Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China

Abstract

Ligustrazine (TMP) is the main active ingredient extracted from Rhizoma Chuanxiong, which is used in the treatment of cardiovascular and cerebrovascular diseases, with the drawback of being unstable and readily sublimated. Cocrystal technology is an effective method to improve the stability of TMP. Three benzoic acid compounds including P-aminobenzoic acid (PABA), 3-Aminobenzoic acid (MABA), and 3,5-Dinitrobenzoic acid (DNBA) were chosen for co-crystallization with TMP. Three novel cocrystals were obtained, including TMP-PABA (1:2), TMP-MABA (1.5:1), and TMP-DNBA (0.5:1). Hygroscopicity was characterized by the dynamic vapor sorption (DVS) method. Three cocrystals significantly improved the hygroscopicity stability, and the mass change in TMP decreased from 25% to 1.64% (TMP-PABA), 0.12% (TMP-MABA), and 0.03% (TMP-DNBA) at 90% relative humidity. The melting points of the three cocrystals were all higher than TMP, among which the TMP-DNBA cocrystal had the highest melting point and showed the best stability in reducing hygroscopicity. Crystal structure analysis shows that the mesh-like structure formed by the O-H⋯N hydrogen bond in the TMP-DNBA cocrystal was the reason for improving the stability of TMP.

Funder

CAMS Innovation Fund for Medical Sciences

Publisher

MDPI AG

Link

https://www.mdpi.com/1420-3049/29/10/2208/pdf

Reference40 articles.

1. Crystal engineering of pharmaceutical cocrystals in the discovery and development of improved drugs;Bolla;Chem. Rev.,2022

2. Xu, J., Shi, Q., Wang, Y.A., Wang, Y., Xin, J.B., Cheng, J., and Li, F. (2023). Recent Advances in Pharmaceutical Cocrystals: A Focused Review of Flavonoid Cocrystals. Molecules, 28.

3. Singh, M., Barua, H., Jyothi, V.G.S.S., Dhondale, M.R., Nambiar, A.G., Agrawal, A.K., Kumar, P., Shastri, N.R., and Kumar, D. (2023). Cocrystals by Design: A Rational Coformer Selection Approach for Tackling the API Problems. Pharmaceutics, 15.

4. New cocrystal of ubiquinol with high stability to oxidation;Bofill;Cryst. Growth Des.,2020

5. Temozolomide–hesperetin drug–drug cocrystal with optimized performance in stability, dissolution, and tabletability;Wang;Cryst. Growth Des.,2021